Dementia and behavioral crisisMANAGEMENT

PSYCHIATRIC PRESENTATIONS · 12 SECTIONS

⚲

596 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Acute anxiety Acute psychosis Agitation-behavioral emergency Anorexia Nervosa (Medical Complications)Bipolar disorder Bipolar Disorder (Depressive Episode)Bipolar Disorder (Manic Episode)Bulimia Nervosa (Medical Complications)Catatonia Conversion disorder Dementia and behavioral crisis Factitious Disorder Failure to Cope (Social)Failure to Thrive Generalized Anxiety Disorder Homicidal Ideation Major Depressive Disorder Major depressive episode Malingering Neuroleptic malignant syndrome Panic Attack Post-Traumatic Stress Disorder (Acute)Schizophrenia Exacerbation Suicidal Ideation Suicidal ideation and attempt Suicide Attempt

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp52

Immediate safety and de-escalation

›Safety priorities

›Scene and staff safety

›Exit access and reduced physical crowding

›Security support for combative behavior

›Verbal de-escalation first

›Calm low-stimulation approach before any restraint

›Familiar caregiver at bedside when available

›Least restrictive intervention ladder

›Environmental and behavioral measures before medication

›Medication before mechanical restraint

›Restraint reserved for imminent danger

Delirium superimposed on dementia as the key discriminator

›Discriminator framework

›Acute change from a documented cognitive and functional baseline

›Collateral source required rather than the patient's own report

›Hours to days time course favors delirium over dementia progression

›Fluctuation and inattention

›Waxing and waning alertness across the encounter

›Inattention disproportionate to known baseline dementia severity

›Default working assumption

›Treat new behavioral change in dementia as delirium superimposed on dementia until a medical cause is excluded

›Full delirium etiology workup deferred to the delirium-specific pathway once superimposition is identified

Rapid reversible and medical threats

›Immediate bedside checks

›Point-of-care glucose

›If glucose below 3.9 mmol/l, immediate dextrose per protocol

›If glucose above 16.7 mmol/l, hyperosmolar state or infection workup

02History/hx69

Behavioral symptom characterization and timeline

›Symptom domains

›Agitation and aggression

›Verbal aggression

›Physical aggression toward caregivers

›Psychotic features

›Visual hallucinations

›Paranoid delusions

›Mood and apathy

›Depressive withdrawal

›Apathy versus depression distinction

›Wandering and disinhibition

›Exit-seeking behavior

›Social or sexual disinhibition

›Time course

›Onset relative to baseline

›Acute hours to days change

›Gradual weeks to months change

›Diurnal pattern

›Sundowning worsening in late afternoon and evening

›Sleep-wake cycle disruption

Baseline cognitive and functional status

›Collateral-derived baseline

›Known dementia diagnosis and stage

›Mild moderate or severe stage

›Prior neuropsychological testing if available

›Functional baseline

›Activities of daily living independence level

03Physical Exam/exam48

General appearance and mental status

›Global assessment

›Level of arousal

›Hypervigilance

›Somnolence

›Attention testing

›Digit span or days of week backward

›Inattention as a delirium marker

›Speech and behavior

›Agitation level

›Perseveration or word-finding difficulty

›Thought content

›Hallucination type

›Visual hallucinations suggesting dementia with Lewy bodies

›Auditory hallucinations

›Delusion themes

›Misidentification delusions

›Paranoid theft delusions

Vital signs and occult medical triggers

›Vital sign abnormalities

›Fever

›Infection concern

›Absent fever does not exclude infection in frail elderly patients

›Tachycardia or hypotension

›Dehydration

›Sepsis

›Hypoxia

›Baseline oxygen requirement comparison

04Differential Diagnosis/ddx67

Delirium superimposed on dementia

›Discriminating features

›Acute onset and fluctuation

›Hours to days course measured against the known dementia trajectory

›Confusion Assessment Method criteria applied against the documented baseline

›Common precipitants in this population

›Urinary tract infection

›Pneumonia

›Dehydration

›New deliriogenic medication

›Coding anchor

›ICD-10 F05 delirium due to known physiological condition

›Includes delirious presentations superimposed on preexisting dementia

›Approach when superimposition is identified

›Treat as delirium and pursue the underlying medical cause

›Full etiology workup follows the delirium-specific pathway

›Behavioral treatment here is bridging supportive care, not definitive management

Dementia subtypes with prominent behavioral and psychological symptoms

›Alzheimer disease

›ICD-10 G30 Alzheimer disease

›Coded with a secondary dementia code specifying presence or absence of behavioral disturbance

›Gradual decline with behavioral prominence typically in later stages

›Dementia with Lewy bodies

›ICD-10 G31.83

›Core features

›Fluctuating cognition

›Recurrent detailed visual hallucinations

›Spontaneous parkinsonism

05Laboratory Tests/lt31

Core screening labs

›Baseline screening set

›Point-of-care and serum glucose

›Hypoglycemia as an immediately reversible cause

›Hyperglycemia and hyperosmolar state concern

›Electrolytes and renal function

›Sodium abnormality as a common reversible contributor

›Acute kidney injury altering medication clearance

›Complete blood count

›Leukocytosis suggesting infection

›Leukocytosis may be blunted or absent in frail elderly infection

›Urinalysis and urine culture

›Interpretation trap

›Asymptomatic bacteriuria is common in this population and often not causal

›Treat urinalysis findings as supportive only, not diagnostic, absent systemic signs

Targeted labs by scenario

›Cardiac and medication safety labs

›Potassium and magnesium before QT-prolonging antipsychotic dosing

›Hypokalemia and hypomagnesemia increase torsades risk

›Correct before or concurrent with treatment when feasible

›Drug level or toxicology when a specific exposure is suspected

›Digoxin level if on digoxin with new confusion

›Lithium level if on lithium with new confusion

›Infection and metabolic workup

›Lactate for sepsis concern when respiratory or systemic signs present

›Liver enzymes and ammonia when a hepatic cause is suspected

›Ammonia interpreted only with a compatible history and appropriate caution

›Thyroid stimulating hormone

06Diagnostic Tests/dt40

Scoring Systems

›Assessment tools

›Confusion Assessment Method

›Acute onset and fluctuating course

›Inattention

›Disorganized thinking or altered consciousness

›Applied against the collateral-reported baseline, not population norms

›Neuropsychiatric Inventory

›Behavioral domain severity and frequency scoring

›Caregiver distress subscale

›Cohen-Mansfield Agitation Inventory

›Physically aggressive behavior subscale

›Physically nonaggressive behavior subscale

›Richmond Agitation-Sedation Scale

›Used to titrate and document sedation level after medication

MRI

›MRI brain indications

›New focal deficit with a nondiagnostic CT

›Small cortical or posterior fossa infarct

›Atypical or rapidly progressive dementia course

›Diffusion restriction pattern raising prion disease concern

›Autoimmune or paraneoplastic encephalitis pattern

›Practical limitation

›Sedation and cooperation requirement

›Often deferred to outpatient neurology once an acute cause is excluded

›CT head indications

›Fall or head trauma with anticoagulant use

07Disposition/dispo38

Level of care and consult triggers

›Disposition criteria

›Medical admission triggers

›Delirium superimposed on dementia confirmed or strongly suspected

›Unstable vital signs or an identified infection requiring inpatient treatment

›Injury from a fall or from restraint requiring further workup

›Psychiatric or geriatric behavioral unit triggers

›Refractory dangerous behavior despite ED management

›No safe discharge environment available

›Discharge candidacy

›Reversible precipitant treated and behavior returned to baseline

›Safe supervised environment confirmed

›Consultation plan

›Geriatrics or geriatric psychiatry consultation

›New or escalating antipsychotic use

›Diagnostic uncertainty about dementia subtype

›Neurology consultation

›New focal deficit or seizure

›Rapidly progressive dementia concern

›Social work consultation

›Caregiver burnout or an unsafe home situation

›Elder abuse or neglect concern

Transfer, placement, and legal considerations

›Transfer considerations

›Facility capability mismatch

›No inpatient geriatric psychiatry bed

›No neurology or neuroimaging capability

›Safe transport

08Treatment/t152

Nonpharmacologic de-escalation and first-line behavioral management

›Behavioral strategies

›Communication techniques

›Simple short sentences and one instruction at a time

›Validate the emotion rather than argue with delusional content

›Environmental modification

›Reduce noise, lighting, and unfamiliar staff turnover

›Familiar objects, photos, or caregiver presence at bedside

›Reorientation and redirection

›Gentle reorientation when tolerated

›Distraction toward a preferred activity

›Unmet-need correction

›Hunger, thirst, toileting, and pain addressed before sedation

›Hearing aids and glasses returned when available

›Evidence context

›Nonpharmacologic approaches are first-line for behavioral and psychological symptoms of dementia

›Preferred over medication whenever time and safety allow

›Reduces the need for restraint and medication adverse effects

Treat the reversible medical driver first

›Driver-directed treatment

›Pain

›Acetaminophen PO or IV 650 mg to 1000 mg every 6 hours

›Maximum 3000 mg per 24 hours in frail elderly patients, 4000 mg per 24 hours if no hepatic impairment

›Scheduled dosing preferred over as-needed dosing in nonverbal patients with an identified pain source

›Opioid analgesia for severe pain

›Morphine IV 2 mg to 4 mg, repeat every 15 to 20 minutes as needed

›Lowest effective dose given delirium and oversedation risk

›Avoid meperidine IV or IM 25 mg to 50 mg as an analgesic option, it carries a disproportionate neurotoxic and deliriogenic risk in this population

›Constipation and urinary retention

›Disimpaction or laxative therapy for fecal impaction

›Bladder decompression for urinary retention

›Infection

›Source-directed antibiotics reserved for confirmed infection, not for isolated asymptomatic bacteriuria

›Home dementia medication continuity

›Continue the home cholinesterase inhibitor and memantine through the ED stay

›Abrupt discontinuation risks rebound behavioral worsening

›Restart promptly if inadvertently held

Antipsychotics for severe agitation, aggression, or psychosis

›Boxed warning framing

›All antipsychotics carry an FDA boxed warning for increased mortality in older adults with dementia-related psychosis

›Risk of death approximately 1.6 to 1.7 times that of placebo across pooled trials, mainly cardiovascular and infectious causes

›Not an approved indication, used off-label only when nonpharmacologic measures fail and danger is imminent

›Use the lowest effective dose for the shortest duration

›Reassess the need for continuation daily

›Document failed nonpharmacologic measures and imminent danger before initiating

›Oral options for cooperative patients

›Risperidone PO 0.25 mg to 0.5 mg

›Repeat 0.25 mg to 0.5 mg after 2 hours if needed

›Typical acute maximum 1 mg to 2 mg per 24 hours in frail elderly patients

›Higher stroke risk signal among atypical antipsychotics noted specifically in this population

›Quetiapine PO 12.5 mg to 25 mg

›Repeat 12.5 mg to 25 mg after 2 hours if needed

›Typical acute maximum 100 mg per 24 hours in frail elderly patients

›Preferred agent when parkinsonism or dementia with Lewy bodies is suspected because of its lower antidopaminergic potency

›Aripiprazole PO 2 mg

›Repeat 2 mg after 2 hours if needed

›Typical acute maximum 10 mg per 24 hours in frail elderly patients

›Parenteral options for uncooperative severe agitation

›Haloperidol IM 0.25 mg to 0.5 mg

›Repeat 0.25 mg to 0.5 mg every 30 to 60 minutes if needed

›Typical acute maximum 2 mg to 3 mg per 24 hours in frail elderly patients, well below the general adult agitation dose

›Deceleration step, switch to dosing every 2 to 4 hours once agitation begins to settle rather than continuing rapid repeat boluses

›Extrapyramidal symptom mitigation

›Benztropine 0.5 mg to 1 mg IM or IV for acute dystonia

›Diphenhydramine 25 mg IM or IV for acute dystonia, avoid as a routine sedative given its own anticholinergic delirium risk

›QT precaution

›Obtain ECG before dosing when feasible and risk factors are present

›Avoid further dosing if QTc exceeds 500 ms or rises 60 ms or more from baseline

›Baseline bundle branch block widens the QRS and can spuriously prolong the QTc, interpret in that context

›Avoid entirely with known long QT syndrome or a recent torsades history

›Olanzapine IM 2.5 mg to 5 mg

›Repeat 2.5 mg after 2 hours if needed

›Typical acute maximum 10 mg per 24 hours in frail elderly patients

›Avoid a parenteral benzodiazepine within 1 hour of IM olanzapine, reported risk of excessive sedation and cardiorespiratory depression

›Contraindicated or high-caution scenario

›Dementia with Lewy bodies or Parkinson disease dementia

›Neuroleptic sensitivity reaction risk with any antipsychotic, including severe rigidity, autonomic instability, and reported fatalities

›If an antipsychotic is unavoidable, quetiapine at the lowest listed dose is preferred, haloperidol and risperidone are avoided

Adjunct and alternative pharmacotherapy

›Benzodiazepines

›General caution

›Paradoxical agitation and worsened confusion are common in dementia

›Reserved for alcohol or benzodiazepine withdrawal, seizure-related agitation, or when antipsychotics are contraindicated by Lewy body sensitivity

›Lorazepam PO IM or IV 0.25 mg to 0.5 mg

›Repeat 0.25 mg to 0.5 mg every 30 to 60 minutes if needed

›Typical acute maximum 1 mg per 24 hours in frail elderly patients outside withdrawal protocols

›Increased fall and respiratory depression risk with repeat dosing

›Trazodone for agitation and sleep-wake disruption

›Trazodone PO 25 mg to 50 mg at bedtime

›Orthostatic hypotension and fall risk

›Not appropriate for acute severe agitation, onset is too slow

›Citalopram as an evidence-based option outside the acute window

›Citalopram PO starting 10 mg daily, target dose studied at 30 mg daily in the CitAD trial

›Current FDA guidance caps citalopram at 20 mg daily in patients over 60 years for QT prolongation risk, creating tension with the higher trial dose

›Not an acute ED intervention, initiated as part of ongoing outpatient or inpatient management

›Melatonin for circadian and sundowning-predominant disturbance

›Melatonin PO 3 mg to 6 mg at bedtime

›Low-risk adjunct with modest evidence

›Not effective for acute severe agitation

Physical restraint and monitoring after sedation

›Restraint principles

›Indications

›Imminent danger to self or others after failed de-escalation

›Bridge to pharmacologic control, not a substitute for it

›Technique

›Least restrictive effective method

›Continuous direct observation while restrained

›Medical risks of restraint

›Positional asphyxia risk, especially prone or supine restraint with reduced respiratory reserve

›Rhabdomyolysis and skin breakdown with prolonged struggle

›Removal criteria

›Reassess for removal at defined intervals rather than leaving restraints in place by default

›Monitoring bundle after parenteral sedation

›Vital sign and pulse oximetry cadence

›Every 15 minutes for the first hour after a parenteral antipsychotic or benzodiazepine

›Every 30 to 60 minutes thereafter until mental status returns to baseline

›ECG and electrolyte monitoring

›Repeat ECG if cumulative antipsychotic dosing is high or QT risk factors are present

›Correct hypokalemia and hypomagnesemia during the same encounter

›Escalation trigger

›Continuous pulse oximetry and airway readiness for any desaturation

Iatrogenic harm review for routine ED interventions

›Intervention-by-intervention review

›Intubation and sedation for airway management

›Deep sedation and anesthetic agents worsen delirium and postoperative cognitive decline in dementia

›Anticholinergic induction agents avoided when an alternative exists

›Procedural or agitation sedation

›Antipsychotic and benzodiazepine mortality and fall signals apply directly, see the antipsychotic and benzodiazepine sections above

›Oversedation can mask an evolving medical emergency such as stroke or sepsis

›Fluid loading

›Dehydration from reduced intake is common and often undertreated

›Aggressive volume resuscitation risks precipitating heart failure in frail elderly patients with reduced cardiac reserve

›Oxygen therapy

›Hypoxia correction can rapidly improve agitation

›Chronic carbon dioxide retainers need a lower titrated target rather than a flat saturation goal

›Vasopressors

›Not routinely indicated, reserved for confirmed septic or cardiogenic shock

›Increased arrhythmia risk when combined with QT-prolonging antipsychotics

›Mechanical circulatory support including intra-aortic balloon pump

›Not applicable to behavioral crisis management absent a separate concurrent cardiac emergency

›Anticoagulation

›Fall risk from agitation and gait instability complicates ongoing anticoagulation decisions

›Do not stop a clinically indicated anticoagulant solely for behavioral agitation without a specific bleeding event or planned procedure

›Fibrinolysis

›Not applicable absent a concurrent acute ischemic stroke or other approved indication

›Analgesia

›Untreated pain is a major agitation driver, see reversible driver treatment above

›Opioids can worsen confusion, use the lowest effective dose and avoid meperidine

›Troubleshooting when behavior does not improve

›Reassess for a missed reversible driver

›Occult pain, urinary retention, or fecal impaction not yet addressed

›Alcohol or benzodiazepine withdrawal emerging

›Reassess for a medication adverse effect

›Akathisia mistaken for worsening agitation

›Emerging neuroleptic sensitivity reaction in unrecognized dementia with Lewy bodies

›Escalate diagnostic suspicion

›Reconsider CT or MRI if a new focal deficit or rapid decline has emerged since arrival

›Reconsider psychiatry or neurology consultation if refractory to two medication classes

09Special Populations/sp34

Pregnancy

›Pregnancy considerations

›Rarity in this topic

›Dementia in pregnancy-age women is rare, consider early-onset genetic dementia or reversible mimics first

›Reversible causes prioritized, including autoimmune encephalitis and metabolic derangement

›Medication safety if treatment is needed

›Haloperidol has the most obstetric safety experience among antipsychotics if treatment is unavoidable

›Avoid benzodiazepines in the first trimester when possible

›Caregiver context

›Pregnant caregivers of a person with dementia may need occupational and physical safety guidance around restraint-level behaviors

Geriatric

›Older adult considerations

›Pharmacokinetic changes

›Reduced renal and hepatic clearance prolongs drug effect

›Increased sensitivity to sedation and hypotension

›Dosing principle

›Start at the lowest listed geriatric dose and titrate slowly

›Avoid stacking multiple sedating agents within a short interval

›Anticholinergic burden

›Cumulative anticholinergic exposure worsens cognition and function

›Avoid diphenhydramine and other high-anticholinergic agents as routine sedatives

›Falls and frailty

›Orthostatic hypotension screening before and after sedating medication

›Fracture risk raises the stakes of any fall during agitation or restraint

›Beers Criteria alignment

›Antipsychotics avoided for behavioral and psychological symptoms of dementia unless nonpharmacologic options have failed and there is risk of harm to the patient or others

›Benzodiazepines avoided as routine agents in this population for the same reason

10Background/b30

Epidemiology

›Epidemiologic figures

›Dementia prevalence

›Roughly 7 to 8 percent of adults over age 65 in the United States live with dementia

›Prevalence roughly doubles approximately every 5 years after age 65

›Behavioral and psychological symptoms of dementia

›Present in roughly 80 to 90 percent of people with dementia at some point in the disease course

›Agitation and aggression are among the most common reasons for ED presentation in this population

›Outcomes

›Behavioral symptoms are a leading driver of caregiver burnout and nursing home placement

›Delirium superimposed on dementia is associated with substantially higher mortality and accelerated cognitive decline than either condition alone

Pathophysiology

›Mechanistic framing

›Neurodegenerative circuit disruption

›Frontal and limbic circuit dysfunction underlies disinhibition and apathy

›Cholinergic deficit contributes to attention and behavioral instability

›Lewy body-specific mechanism

›Alpha-synuclein pathology in cortical and subcortical structures

›Dopaminergic sensitivity explains the severe antipsychotic reaction risk

›Delirium superimposed mechanism

›Reduced cognitive reserve lowers the threshold for a systemic insult to produce delirium

›Neuroinflammation and neurotransmitter imbalance from the precipitating illness

Therapeutic Considerations

›Treatment principles

›Reversible causes treated first

›Medical precipitants excluded and treated before attributing behavior to dementia progression

›Nonpharmacologic measures preferred

›Lower harm profile than any pharmacologic option

11Patient Discharge Instructions/pdi20

Copy discharge instructions

›Discharge instructions

›Condition summary

›Behavioral episode evaluated and reversible causes addressed

›Current dementia stage and expected fluctuation explained to the caregiver

›Medication guidance

›Take new or adjusted medications exactly as directed

›Do not stop the home cholinesterase inhibitor or memantine without discussing it with a physician

›Home safety planning

›Remove access to weapons, car keys, and stove controls if unsafe

›Supervision plan for the next 24 to 48 hours

Return precipitants and caregiver guidance

›Return to ED now

›New fever above 38.0 degrees Celsius

›New weakness, facial droop, or slurred speech

›Inability to wake the patient or worsening unresponsiveness

›Repeat falls or a fall with head injury

›No improvement in agitation within 24 to 48 hours of the new plan

›Caregiver support resources

›Local caregiver respite and support group referral

›Follow-up with primary care or geriatrics within 1 week

›Follow-up with geriatric psychiatry or neurology if an antipsychotic was started

12References/r15

Guidelines and key sources

›Core references

›American Psychiatric Association 2016 practice guideline on use of antipsychotics to treat agitation or psychosis in patients with dementia

›Recommends antipsychotics only after nonpharmacologic approaches have failed and risk of harm is present

›Recommends the lowest effective dose and periodic attempts to taper

›FDA boxed warning on atypical and conventional antipsychotics in elderly patients with dementia-related psychosis

›Increased mortality risk demonstrated in placebo-controlled trials

›American Geriatrics Society Beers Criteria for potentially inappropriate medication use in older adults

›Antipsychotics and benzodiazepines both flagged for avoidance in behavioral and psychological symptoms of dementia except in selected circumstances

›CATIE-AD trial, Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer Disease

›Found no significant overall advantage in time to treatment discontinuation for atypical antipsychotics over placebo when balancing modest efficacy against adverse effects

›CitAD trial of citalopram for agitation in Alzheimer disease

›Demonstrated improvement in agitation with citalopram versus placebo at a dose exceeding the current FDA elderly QT guidance

›Fourth consensus report of the Dementia with Lewy Bodies Consortium

›Emphasizes antipsychotic avoidance or extreme caution due to neuroleptic sensitivity

›Confusion Assessment Method validation literature for delirium superimposed on dementia detection

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.